Epilepsy Clinical Trials in New York

Showing 61-80 of 155 trials

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

NCT02758626

This is a phase 2, crossover study of Ataluren for the treatment of nonsense mutation Dravet syndrome or cyclin-dependent kinase-like 5 (CDKL5) deficiency, resulting in drug-resistant epilepsy. Patients will receive 12 weeks of ataluren or placebo during each treatment period. Treatment Period 1 will be followed by a 4-week Washout Period. Based on ataluren PK and pharmacodynamic data, the 4-week washout period is deemed an appropriate length of time to eliminate any ataluren drug effects. Following the Washout Period, patients will crossover to receive the opposite treatment during Treatment Period 2 as follows: Patients receiving ataluren during Treatment Period 1 will receive placebo during Treatment Period 2. Patients receiving placebo during Treatment Period 1 will receive ataluren during Treatment Period 2.

Epilepsy

NYU Langone Health15 participantsStarted Nov 2016

New York, New York, United States

COMPLETEDPhase 3< 1 mile

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208

The study will evaluate the effectiveness and safety of an investigational drug-ganaxolone - on partial seizure frequency in adults with epilepsy taking a maximum of 3 antiepileptic medications (AEDs).

Drug Resistant Partial Onset Seizure

Marinus Pharmaceuticals405 participantsStarted Oct 2013

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +68 more locations

Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

Epilepsy Trials in Other Cities

Long-term Cardiac Monitoring in Epilepsy

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

Staccato Alprazolam and Photoparoxysmal Response

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

Neuroimaging Biomarker for Seizures

Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

Diffusion MRI-1 Imaging Database

Other Conditions in New York